Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report
Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report
复制标题
DOI：
10.1177/0269881114523865
复制
发表时间：
2014-07-01
影响因子：
4.1
通讯作者：
Hulse, Gary
中科院分区：
文献类型：
--
作者：
Kelty, Erin;Martyn, Vlad;Hulse, Gary
特发性睡眠过度（IH）是一种罕见的睡眠障碍，最近假设与促进γ-氨基丁酸（GABA）与GABA受体结合的分子的产生有关。本文报告了1例IH患者的治疗，该患者接受了96小时连续低剂量（4 mg/天）输注苯二氮卓类拮抗剂氟马西尼，随后使用缓释氟马西尼植入剂。使用氟马西尼减轻了患者的IH症状，包括白天过度嗜睡，睡眠醉酒和自我报告的认知问题。该病例为短期（皮下（SC）给药）和长期（植入）氟马西尼给药提供了可能的治疗和系统。目前的数据支持需要进一步研究使用氟马西尼治疗IH和开发长期氟马西尼输送系统。
Idiopathic hypersomnia (IH) is a rare sleep disorder, recently hypothesized to be related to the production of a molecule that facilitates the binding of gamma-aminobutyric acid (GABA) to the GABA receptor. This paper reports on the treatment of a patient with IH who was treated with a 96-hour continuous low dose (4 mg/day) infusion of a benzodiazepine antagonist, flumazenil, followed by a slow-release flumazenil implant. The use of flumazenil mitigated the patient's IH symptoms including excessive daytime sleepiness, sleep drunkenness and self-reported cognitive problems. The case both provides a possible treatment and system for short (subcutaneous (SC) administration) and longer term (implant) flumazenil delivery. Current data supports the need for further research into the use of flumazenil for the treatment of IH and to develop long term flumazenil delivery systems.